.png){kind=icon}
返回
KRAS mutations: Analytical considerations
.png){kind=icon}
PRE
AI
DOI：10.1016/j.cca.2014.01.049.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer death globally. Significant improvements in survival have been made in patients with metastasis by new therapies. For example, Cetuximab and Panitumumab are monoclonal antibodies that inhibit the epidermal growth receptor (EGFR). KRAS mutations in codon 12 and 13 are the recognized biomarkers that are analyzed in clinics before the administration of anti-EGFR therapy. Genetic analyses have revealed that mutations in KRAS predict a lack of response to Panitumumab and Cetuximab in patients with metastatic CRC (mCRC). Notably, it is estimated that 35-45% of CRC patients harbor KRAS mutations. Therefore, KRAS mutation testing should be performed in all individuals with the advanced CRC in order to identify the patients who will not respond to the monoclonal EGFR antibody inhibitors. New techniques for KRAS testing have arisen rapidly, and each technique has advantages and disadvantages. Herein, we review the latest published literature specific to KRAS mutation testing techniques. Since reliability and feasibility are important issues in clinical analyses. Therefore, this review also summarizes the effectiveness and limitations of numerous KRAS mutation testing techniques. (C) 2014 Elsevier B.V. All rights reserved.
Keyword:
Colorectal cancer
KRAS gene
Mutation
Method and mutation analysis
期刊
IF:
2.9
论文数:
1.6W
被引数:
2.1W
机构
引用论文
Interpreting Internal Activation Patterns in Deep Temporal Neural Networks by Finding Prototypes
OAAI
OAAI分享收藏Coamplification at Lower Denaturation Temperature-PCR Increases Mutation-Detection Selectivity of TaqMan-Based Real-Time PCR.png)
CLINICAL CHEMISTRY
OAAI
CLINICAL CHEMISTRYIF6.3
OAAI分享收藏The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patientsANNALS OF ONCOLOGYOAAI
ANNALS OF ONCOLOGYIF65.4
OAAI分享收藏Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?GENETICS IN MEDICINEOAAI
GENETICS IN MEDICINEIF6.2
OAAI分享收藏KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerKRAS密码子61，146和BRAF突变预测KRAS密码子12和13野生型转移性结直肠癌对西妥昔单抗加伊立替康的耐药性OAAI
OAAI分享收藏分享收藏A standardized framework for the validation and verification of clinical molecular genetic testsOAAI
OAAI分享收藏
查看更多内容